On August 7, 2023, ELANCO ANIMAL HEALTH ($NYSE:ELAN) reported their financial earnings for their second quarter of their fiscal year 2023. Total revenue was USD 1057.0 million, a 10.2% decrease from the same period in the previous year. Net income for the quarter was USD -97.0 million, a decrease from the previous year’s loss of -22.0 million.
On Monday, August 7, 2023, ELANCO ANIMAL HEALTH reported its fiscal year 2023 second quarter earnings results. The stock opened at $12.2 and closed at $12.1, representing an increase of 4.0% from the previous closing price of $11.6. ELANCO ANIMAL HEALTH’s performance in the second quarter of FY2023 reflects positively on the company as it continues to strive towards its long-term goals. This demonstrates ELANCO’S ability to successfully grow its business and meet the changing needs of customers and stakeholders. ELANCO also reported strong growth in its core animal health business, driven by strong market demand for its products and services.
This suggests that ELANCO continues to operate efficiently and generate value for shareholders. Overall, ELANCO ANIMAL HEALTH’s quarterly performance was encouraging and demonstrates the company’s ability to successfully navigate difficult market conditions and create value for customers and investors alike. With its strong financial performance, ELANCO is well positioned for future growth and success. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for ELAN. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for ELAN. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for ELAN. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for ELAN are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
Analysis – ELAN Intrinsic Value Calculator
At GoodWhale, we performed an analysis of ELANCO ANIMAL HEALTH’s wellbeing. According to our proprietary Valuation Line, the fair value of ELANCO ANIMAL HEALTH share is around $22.9. Currently, ELANCO ANIMAL HEALTH’s stock is traded at $12.1 – which is 47.2% undervalued. These results show that there are opportunities to increase the value of ELANCO ANIMAL HEALTH’s stock. We thus suggest investors to consider buying ELANCO ANIMAL HEALTH stock at the current market price. More…
Risk Rating Analysis
Star Chart Analysis
The company’s competitors include GeneFerm Biotechnology Co Ltd, Rhone Ma Holdings Bhd, and Phibro Animal Health Corp.
– GeneFerm Biotechnology Co Ltd ($TPEX:1796)
Ferm Biotechnology Co Ltd is a company that manufactures and sells biotechnology products. The company has a market cap of 2.34B as of 2022 and a return on equity of 9.05%. The company’s products are used in the healthcare, food and beverage, and industrial markets.
– Rhone Ma Holdings Bhd ($KLSE:5278)
Rhone Ma Holdings Bhd is a Malaysia-based investment holding company. The Company, through its subsidiaries, is engaged in the provision of management services, banking and financial services, and investment holding. The Company’s segments include Commercial Banking, which is engaged in the provision of banking products and services to small and medium enterprises (SMEs) and individuals; Treasury, which is engaged in the provision of foreign exchange and money market services; and Corporate Banking, which is engaged in the provision of financing solutions to SMEs and large corporations.
– Phibro Animal Health Corp ($NASDAQ:PAHC)
Phibro Animal Health Corp is a publicly traded company that focuses on animal health and nutrition. As of 2022, the company had a market capitalization of 505.49 million and a return on equity of 19.25%. Phibro Animal Health Corp was founded in 1947 and is headquartered in Teaneck, New Jersey. The company’s products include pharmaceuticals, vaccines, and nutritional supplements for livestock, poultry, and aquaculture.
Investors should be aware of ELANCO ANIMAL HEALTH’s second quarter earnings results for FY2023, which were reported on August 7 2023. The company experienced a total revenue decrease of 10.2%, to USD 1057.0 million, and a net income loss of -97.0 million compared to -22.0 million in the same quarter last year. Despite this, the stock price moved up the same day, suggesting that investors may still be optimistic about ELANCO ANIMAL HEALTH’s future prospects. As such, potential investors should do their research to determine the risks and rewards of investing in this company.